Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established player and fully integrated provider of novel imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, has announced that prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with piflufolastat F 18 has been included in recently updated National Comprehensive Cancer Network® (NCCN) Guidelines® for prostate cancer. The NCCN Guidelines® are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors.
The Lantheus’
product, PYLARIFY® (piflufolastat F18) injection, is a radioactive diagnostic
agent indicated for PET imaging of PSMA positive lesions in men with prostate
cancer: with suspected metastasis who are candidates for initial definitive
therapy and/or with suspected recurrence based on elevated serum
prostate-specific antigen (PSA) level. PYLARIFY was approved by the U.S. Food
and Drug Administration (FDA) in May 2021 and remains the first and only
commercially available PSMA-targeted PET imaging agent for prostate cancer.
To
read more please visit:
Source: Lantheus